Welcome to our dedicated page for Collplant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CollPlant Biotechnologies Ltd (NASDAQ: CLGN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. CollPlant files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents include press releases on financial results, product development updates, distribution agreements, corporate governance matters and interim financial statements.
Through its Form 6-K submissions, CollPlant furnishes materials such as quarterly financial results, condensed consolidated interim financial statements, operating and financial reviews, and detailed press releases on topics like expansion of rhCollagen distribution capabilities in North America, positive non-clinical data for its photocurable dermal and soft tissue filler, and distribution expansion for its Vergenix STR tendon-repair product in Europe. Filings also cover announcements related to scientific collaborations, including studies involving its Collink.3D rhCollagen-based bioink and Mayo Clinic’s fully humanized 3D bioprinted skin model, as well as notices of shareholder meetings and proxy materials.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand financial performance, progress in regenerative and aesthetic medicine programs, and material agreements such as CollPlant’s development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company. Real-time updates from EDGAR ensure that new 6-K and 20-F reports are available promptly.
Users can review CollPlant’s historical and current filings to analyze trends in its rhCollagen-based business, monitor disclosures about collaborations and product pipelines, and better understand the regulatory context of its 3D bioprinting, tissue repair and medical aesthetics activities.